Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia.
The tools now are available to characterize oxygenation/hypoxia in the clinic. The clinical investigations conducted thus far have shown that significant regions of hypoxia exist in solid tumors in patients. Of the various strategies developed in the laboratory for reducing (or eliminating) hypoxia in tumors, the intravenous administration of nontoxic oxygen-carrying materials is probably the most generally applicable in a clinical setting.
Teicher
B A
BA
Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
D000740:Anemia / Q000209:etiology / Q000517:prevention & control; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D015687:Cell Hypoxia / Q000187:drug effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004338:Drug Combinations; D004351:Drug Resistance / Q000502:physiology*; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D005466:Fluorocarbons / Q000627:therapeutic use; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D006931:Hyperbaric Oxygenation; D015993:Life Tables; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology* / Q000532:radiotherapy; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy; D010100:Oxygen / Q000008:administration & dosage / Q000378:metabolism*; D010108:Oxyhemoglobins / Q000378:metabolism; D011836:Radiation Tolerance / Q000502:physiology; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D016019:Survival Analysis; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; D010108:Oxyhemoglobins; D014665:Vasodilator Agents; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D010100:Oxygen